Navigation Links
BUSM professor awarded $13.3 million to study potential treatments to prevent STDs
Date:8/12/2011

(Boston) Deborah Anderson, PhD, professor of obstetrics and gynecology and microbiology at Boston University School of Medicine (BUSM) is co-leading a new study funded by a five-year $13.3 million grant from the National Institute of Allergy and Infectious Diseases (NIAID). Anderson will investigate the vaginal use of human monoclonal antibodies manufactured transiently in tobacco plants (called "plantibodies") to prevent sexually transmitted infections caused by Herpes Simplex Virus (HSV) and the Human Immunodeficiency Virus (HIV).

The production of human monoclonal antibodies and other proteins in plants is intended to provide a low-cost and large-capacity manufacturing system that could ensure an affordable supply of antibodies, vaccines and other biopharmaceuticals for at-risk populations throughout the world, including developing countries.

The research team will develop ring, film and barrier formulations to deliver the antibodies and conduct preclinical testing in vitro and in vivo using animal models to evaluate safety and antimicrobial (HSV, HIV) efficacy. The plantibodies will be tested for safety and duration of activity in a human pre-phase I clinical trial as a first step towards their use as vaginal microbicides to prevent HSV and HIV infections in women.

"We hope that this research will lead to novel ways of preventing sexually transmitted diseases, which are epidemic in the US and worldwide and have far reaching health, social and economic consequences," said Anderson. "In addition, we will be breaking ground for the potential use of plantibodies to prevent other diseases caused by pathogens that cross mucosal membranes, such as rhinoviruses (common cold) and influenza (flu), as well as dangerous emerging pathogens like the Ebola virus (hemorrhagic fever)."

The grant was awarded through the NIAID-funded Integrated Preclinical/Clinical Program for HIV Topical Microbicides. Kevin Whaley, PhD, at Mapp Biopharmaceuticals in San Diego and Thomas Moench, MD, at ReProtect Inc. in Baltimore, are the main collaborators on this research study.

The research will be conducted by a consortium of investigators at Boston University Medical Campus, University of North Carolina, Johns Hopkins University, Brown University, Emory University, Fenway Community Health, ReProtect LLC, Kentucky BioProcessing LLC, Auritec Pharmaceuticals Inc., Aridis Pharmaceuticals and Mapp Biopharmaceutical Inc.


'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. National Science Foundation grants Clemson professors award to develop nanoprobes
2. University professor stresses links between US Navy sonar and whale strandings
3. Minnesota ecology professor wins international award for biodiversity and biofuels research
4. NJIT professors research suggests changes in underwater data communications
5. 2 Alexander von Humboldt professorships go to LMU Munich
6. Top biophysics award to Professor Ray Norton
7. University of Leicester professor adds new perspective to rainforest debate
8. NJIT professor finds engineering technique to identify disease-causing genes
9. Chemistry professor 1 of only 3 at UH to achieve prestigious AAAS status
10. Florida professor creates endowment for insect scientists
11. Dinner, lecture series to honor legacy of distinguished UH professor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
Breaking Biology Technology: